Shots:
- Alvotech has begun the confirmatory trial of AVT16, biosimilar version of Entyvio (vedolizumab), that targets alpha-4-beta-7 protein for treating Ulcerative Colitis and Crohn’s disease
- The P-III (AVT16-GL-C01) trial is a double-blind, two-arm study comparing the efficacy, safety & immunogenicity of AVT16 vs Entyvio in patients of age 18-80yrs. with moderate to severe active Ulcerative Colitis
- Alvotech’s biosimilars portfolio targets autoimmune, eye, bone, respiratory diseases, and cancer. The company plans marketing applications for 3 biosimilars in 2024, with AVT16 among 6 earlier-stage programs
Ref: Alvotech | Image: Alvotech| Press Release
Related News:- The CHMP Grants Positive Opinion to Samsung Bioepis and Biogen’s Opuviz (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
